Globe Life Inc. (GL) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reflects stable financial performance with strong growth in life and health premiums, positive guidance for 2025, and increased share repurchases. The Q&A section highlights improvements in agent productivity and sales growth, as well as favorable mortality and investment trends. Despite some uncertainties like the EEOC investigation, the overall sentiment is positive, driven by strategic initiatives and robust financial metrics.
Key Financial Performance
Net Income $388 million or $4.73 per share, compared to $303 million or $3.44 per share a year ago. This represents a significant increase, attributed to improved operational performance.
Net Operating Income $394 million or $4.81 per share, an increase of 38% over the $3.49 per share from a year ago. This growth is driven by operational improvements and favorable market conditions.
Return on Equity (GAAP) 21.9% through September 30. This reflects strong profitability and efficient use of equity.
Book Value per Share (Excluding AOCI) $93.63 as of September 30, up 12% from a year ago, driven by operational growth and favorable market conditions.
Total Premium Revenue Grew 5% over the year-ago quarter, reflecting consistent growth in the insurance operations.
Life Premium Revenue Increased 3% from the year-ago quarter to $844 million. Growth is attributed to premium growth and remeasurement gains due to good mortality experience.
Life Underwriting Margin $482 million, up 24% from a year ago, driven by premium growth and favorable mortality and lapse assumptions.
Health Premium Revenue Grew 9% in the quarter to $387 million, driven by premium growth and remeasurement gains.
Health Underwriting Margin $108 million, up 25% due to premium growth and remeasurement gains.
Administrative Expenses $90 million for the quarter, an increase of 1% over the third quarter of 2024, reflecting stable expense management.
American Income Life Premiums Up 5% over the year-ago quarter to $451 million, with underwriting margin up 18% to $261 million.
Liberty National Life Premiums Up 5% over the year-ago quarter to $98 million, with underwriting margin up 57% to $70 million.
Family Heritage Health Premiums Increased 10% over the year-ago quarter to $119 million, with underwriting margin up 49% to $51 million.
Direct-to-Consumer Life Premiums Down 1% over the year-ago quarter to $245 million, but underwriting margin increased 29% to $114 million.
United American Health Premiums Increased 14% over the year-ago quarter to $170 million, with underwriting margin up $2 million to $16 million.
Excess Investment Income $37 million, down approximately $3 million from the year-ago quarter, due to lower growth in average invested assets and lower average earned yield.
Net Investment Income $286 million in the quarter, slightly above last year's third quarter, reflecting stable investment performance.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Life Premium Revenue: Increased 3% from the year-ago quarter to $844 million. Expected to grow between 3% and 3.5% for the full year 2025.
Health Premium Revenue: Grew 9% in the quarter to $387 million. Expected to grow in the range of 8% to 9% for the full year 2025.
New Worksite Enrollment Platform: Developed to improve agent productivity and training at Liberty National.
Direct-to-Consumer Technology: Implemented new technology to enhance underwriting processes, improving conversion of customer inquiries into sales.
Exclusive Agency Force: Currently over 17,500 exclusive agents, with a goal to surpass 28,000 agents and $1.4 billion in annual sales by 2030.
Direct-to-Consumer Channel: Net life sales up 13% from the year-ago quarter, reversing a declining trend. Expected to generate 1 million leads in 2025.
United American Division: Health premiums increased 14% year-over-year to $170 million, driven by Medicare supplement rate increases.
Administrative Expenses: Increased 1% over the third quarter of 2024, remaining at 7.3% of premium.
Investment Operations: Invested $279 million in fixed maturities at an average yield of 6.33% and $86 million in commercial mortgage loans with an average expected cash return of 9%.
Bermuda Reinsurance Affiliate: Progressing towards establishing a Bermuda reinsurance affiliate to reinsure new and in-force life insurance policies, expected to execute the first transaction by the end of 2025.
Share Repurchase Program: Repurchased approximately 840,000 shares for $113 million in Q3 2025. Total share repurchases expected to reach $685 million for the year.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Market Conditions: The company operates in the lower middle to middle income market, which is underserved but also sensitive to economic downturns. This could impact premium revenue and sales growth.
Agent Recruitment and Retention: The company relies heavily on exclusive agents, and fluctuations in agent count could directly affect sales growth. Recruiting individuals without prior insurance experience poses challenges in training and productivity.
Investment Portfolio: The fixed maturity portfolio has a net unrealized loss position of $1.1 billion due to higher market rates. While the company can hold investments to maturity, this could limit liquidity in adverse scenarios.
Regulatory and Compliance Risks: The establishment of a Bermuda reinsurance affiliate is subject to regulatory approvals, and delays or denials could impact the company’s capital and liquidity plans.
Economic Uncertainty: The company’s investment portfolio and underwriting margins could be affected by economic downturns, particularly if there are downgrades or defaults in the BBB-rated bonds, which comprise 43% of the portfolio.
Operational Costs: Administrative expenses are increasing, albeit slightly, which could pressure margins if not managed effectively.
Technology Implementation: The rollout of new technology for underwriting and recruiting is critical for improving efficiency, but delays or failures in implementation could hinder growth.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Total Premium Revenue Growth: For the full year 2025, total premium revenue is expected to grow approximately 5%, slightly higher than in 2024 and consistent with the 10-year average growth rate.
Life Premium Revenue Growth: Life premium revenue is expected to grow between 3% and 3.5% for the full year 2025. For 2026, life premium revenue is anticipated to grow 4% to 5%.
Health Premium Revenue Growth: Health premium revenue is expected to grow in the range of 8% to 9% for 2025 and 9% to 11% for 2026.
Life Underwriting Margin: For 2025, life underwriting margin as a percentage of premium is anticipated to be between 44% and 46%. For 2026, it is expected to be in the range of 40% to 43%.
Health Underwriting Margin: For 2025, health underwriting margin as a percentage of premium is anticipated to be between 25% and 27%. For 2026, it is expected to be in the range of 24% to 27%.
Agent Count Growth: For 2025, average producing agent count is expected to increase as follows: American Income by around 2%, Liberty National by around 4%, and Family Heritage by around 8%.
Net Life Sales Growth: For 2025, net life sales are expected to grow as follows: American Income by around 3%, Liberty National by around 1%, and direct-to-consumer by around 4%. For 2026, net life sales growth is expected to be mid-single-digit for American Income, high single-digit for Liberty National, and low single-digit for direct-to-consumer.
Net Health Sales Growth: For 2025, net health sales are expected to grow as follows: Liberty National flat, Family Heritage by around 13%, and United American by around 50%. For 2026, net health sales growth is expected to be high single-digit for Liberty National, low double-digit for Family Heritage, and mid-single-digit for United American.
Net Operating Earnings Per Share: For 2025, net operating earnings per diluted share are estimated to be in the range of $14.40 to $14.60, representing 17% growth at the midpoint. For 2026, net operating earnings per diluted share are estimated to be in the range of $14.60 to $15.30, representing 3% growth at the midpoint.
Investment Income and Yield: For 2025, net investment income is expected to be flat, with required interest growing around 2%, resulting in a decline in excess investment income of around 10% to 15%. For 2026, the average yield earned on the fixed maturity portfolio is expected to be approximately 5.29%, with a blended earned yield in the range of 5.4% to 5.5%.
Capital and Liquidity: For 2025, share repurchases are expected to total $685 million, with $85 million distributed as dividends. For 2026, parent excess cash flows available for shareholder returns are anticipated to be approximately $600 million to $700 million.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Shareholder dividend payments: The company returned approximately $580 million year-to-date, including $22 million in the third quarter. For the fourth quarter, the company anticipates distributing approximately $20 million in dividends. For the full year 2025, the company intends to distribute approximately $85 million in dividends.
Share repurchase program: The company repurchased approximately 840,000 shares in the third quarter for $113 million at an average price of $134.17 per share. Year-to-date, share repurchases totaled $685 million. The company expects to repurchase $170 million worth of shares in the fourth quarter, supported by an extraordinary dividend from a subsidiary.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What is driving the muted life sales growth in recent quarters, and what gives confidence in reaccelerating growth?
A:The muted sales growth is not due to consumer demand, which remains strong, but rather due to agent productivity and the onboarding of newer agents. The company is seeing an improvement in premium per sale and has increased hires by 17% this quarter. This, along with incentive programs and a focus on recruiting and onboarding, gives confidence in higher agent count growth and sales growth for 2026.
Q:Does the guidance for $600 million to $700 million in excess cash flow for next year include benefits from the Bermuda entity?
A:No, the guidance does not include any benefits from the Bermuda entity. The earliest potential benefit from the Bermuda affiliate would be in 2027, depending on regulatory approvals.
Q:Can you elaborate on the new worksite enrollment platform and recruiting CRM?
A:The new worksite enrollment platform helps agents conduct needs-based analyses with customers, leading to a 20%+ increase in premium production per worksite. The recruiting CRM centralizes data and analytics, enabling real-time tracking of the recruiting pipeline and improving management of new recruits. Both initiatives are expected to enhance sales and recruiting efficiency.
Q:Why are direct-to-consumer sales up 13% while premiums are down 1%?
A:The decline in premium growth is due to prior sales declines impacting the premium base. However, recent positive sales growth is expected to turn around premium earnings. The company is cautiously optimistic about low single-digit sales growth in direct-to-consumer next year, pending Q4 results.
Q:What is the implied EPS guidance for Q4, and why is it lower than the most recent quarter?
A:The implied EPS guidance for Q4 is $3.25 to $3.45, lower than the most recent quarter due to timing of certain items like a research and development tax credit and favorable mortality experience in Q3. Seasonal factors like higher claims in Q4 also contribute to the lower guidance.
Q:What are the expectations for claims trends and sales in the health business?
A:Claims trends have flattened, and rate increases are expected to bring margins back to target profitability in 2026. Sales growth in Medicare Supplement is supported by demographic trends and disruptions in the Medicare Advantage market, which provide a tailwind for the company.
Q:What is the status of the EEOC investigation?
A:The EEOC findings are not binding, and there is no pending litigation. The company has successfully defended its classification of sales agents as independent contractors in past court cases and would vigorously defend any future lawsuits.
Q:What is driving the increase in excess cash flow guidance to $600 million to $700 million?
A:The increase is driven by improving mortality trends, flattening health claim cost trends, and a favorable investment yield environment. The guidance is sustainable, barring significant changes in these factors.
Q:Does the 2026 guidance for life margins include any expectation for remeasurement gains?
A:Yes, the guidance assumes continued favorable mortality experience and remeasurement gains relative to updated assumptions. The high end of the guidance range factors in potential assumption updates.
Q:What are the company’s thoughts on M&A?
A:M&A is not a priority but remains an option if it provides better returns than share repurchases. The company focuses on acquisitions that align with its core business of protection-oriented products for middle and lower-middle-income markets.
Q:What is the expected cadence of life sales growth in 2026?
A:Life sales growth is expected to be back-end weighted due to the time lag between agent recruitment and productivity. Early positive momentum in agent hires bodes well for Q4 and Q1 of next year, with Liberty expected to achieve high single-digit growth and AIL mid-single-digit growth.
Q:What is the size of the extraordinary dividend mentioned, and when was it issued?
A:The extraordinary dividend was $80 million and was issued in 2025.
Q:Why are long-term mortality assumptions not updated to reflect recent favorable trends?
A:The company prefers to see consistent favorable trends over time before updating long-term assumptions, as these are meant to reflect the life of the business. Recent experience is more favorable than pre-pandemic levels, but the company remains cautious.
Q:Review of Unclear Management Responses
A:Management avoided providing a direct answer regarding the EEOC investigation's timeline and resolution, stating only that the findings are not binding and there is no pending litigation. Additionally, they did not provide specific details on the expected timing or financial impact of the Bermuda entity's benefits, citing regulatory dependencies.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Bermuda subsidiary
Chief
DTC
Director Investor
Income increase
Investor Relations
Liberty National
Life Inc
Medicare supplement
National increase
accounting
adjustment
affiliate
agency force
agency health
anticipation
approval
assumption gain
balance sheet
catch
consumer lead
conversion
count term
family
health reserve
increase Liberty
increase projection
insurance company
nature
outlook
process
protection
reminder
reserve balance
sale Liberty
strength
term agent
update midpoint
GL Transcript
Globe Life Inc. (GL) Q4 2025 Earnings Call Transcript
Positive2-5
The earnings call indicates strong financial performance with growth in premium revenues and underwriting margins. Despite some concerns about agent retention and unclear responses on certain strategic initiatives, the optimistic guidance on sales growth and productivity gains, along with stable investment portfolio exposure, suggests a positive market reaction. The company's focus on technology and profitability, along with favorable trends in Medicare Supplement, further supports a positive outlook.
Globe Life Inc. (GL) Q3 2025 Earnings Call Transcript
Positive10-23
The earnings call reflects stable financial performance with strong growth in life and health premiums, positive guidance for 2025, and increased share repurchases. The Q&A section highlights improvements in agent productivity and sales growth, as well as favorable mortality and investment trends. Despite some uncertainties like the EEOC investigation, the overall sentiment is positive, driven by strategic initiatives and robust financial metrics.
Globe Life Inc. (GL) Q2 2025 Earnings Call Transcript
Positive7-24
The earnings call summary and Q&A suggest a positive outlook. Financial performance is stable with expected growth in life and health premiums. The agent count growth and recovery in the Direct-to-Consumer channel are promising. Share repurchases and strategic flexibility from the Bermuda structure are positives. Despite some uncertainties, like ongoing investigations and timing for cash flow benefits, the overall sentiment leans towards optimism, especially with improved guidance and stable margins in the health business.
Earnings call transcript: Globe Life Q1 2025 misses EPS estimates
Positive5-1
The earnings call summary indicates strong financial performance with increased net and operating income, robust shareholder return plans, and optimistic guidance for 2025. Despite some concerns about health underwriting margins and ongoing inquiries, management's confidence in achieving EPS guidance and strategic investments in technology are positive indicators. Share repurchase plans and favorable mortality trends further support a positive outlook. The Q&A session did not reveal significant negative trends or uncertainties, reinforcing the positive sentiment. Given these factors, the stock price is likely to experience a positive movement in the short term.
GL Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
